Hormone Replacement Therapy Explained With Post Pellets

Discover how post-pellet hormone replacement therapy can enhance your well-being through hormone balance and relief from symptoms.

Abstract

In this educational post, I share a comprehensive, patient-centered guide to managing post-pellet hormone replacement therapy (HRT) for both women and men. Drawing from my dual training as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), Family Nurse Practitioner-Board Certified (FNP-BC), Certified Functional Medicine Practitioner (CFMP), Institute for Functional Medicine Certified Practitioner (IFMCP), ATN, and CCST, I integrate the latest evidence-based research with real-world clinical observations from my practice in El Paso, Texas. We explore the unique pharmacokinetics of hormone pellets, the underlying physiology of endocrine feedback loops and tissue conversions, and practical, stepwise protocols for addressing common issues, including androgen excess, estrogen fluctuations, bleeding, headaches, anxiety, and hair changes. I emphasize structured workflows, safety monitoring, and personalized transitions while highlighting how integrative chiropractic care supports nervous system balance, reduces inflammation, and optimizes metabolic and hormonal outcomes. This journey equips readers with clear, actionable insights grounded in modern research to achieve symptom relief, safety, and long-term wellness.

Post-Pellet HRT Foundations: What Patients and Clinicians Need to Know

As a clinician who has guided hundreds of patients through bioidentical hormone replacement therapy (BHRT) using subcutaneous pellets, I have observed that understanding the distinct behavior of these implants is the cornerstone of successful care. Unlike daily topical gels, creams, patches, or weekly injections, pellets provide a slow, sustained release of hormones such as testosterone, estradiol, and sometimes progesterone or DHEA over several months. This delivery method offers convenience and steady baseline levels for many, yet it introduces unique challenges due to its pharmacokinetics.

In my clinical experience at Push as Rx, patients often report an initial surge in energy and mood within the first 1–3 weeks after insertion, followed by a gradual decline. This pattern stems from the pellets’ dissolution dynamics: a higher surface area early on leads to faster hormone diffusion, creating a peak, followed by a tapering tail as the pellet mass decreases (Pastuszak et al., 2012). Compared to injections—which produce sharp day-1 spikes and troughs—or transdermal patches that deliver relatively stable daily doses, **pellets** create a smoother but still variable curve influenced by factors like insertion site vascularity, body mass index (BMI), physical activity, and local tissue responses such as mild inflammation or fibrosis.

**Why this matters physiologically**: Hormone release kinetics directly affect receptor activation in target tissues. Rapid early peaks can overstimulate androgen or estrogen receptors in the brain, skin, endometrium, and vasculature, leading to transient symptoms. I always stress to patients that these fluctuations are expected, not failures of therapy, and that proper education prevents unnecessary worry.

Integrative chiropractic care fits seamlessly here. Spinal adjustments restore proper nervous system signaling to the hypothalamus and pituitary, supporting the hypothalamic-pituitary-gonadal (HPG) axis and reducing sympathetic overdrive, which can exacerbate hormone-related stress or inflammation. In my practice, combining chiropractic care with pellet therapy has helped patients maintain better posture, mobility, and metabolic health, which in turn supports more stable hormone utilization.

Why Pellets Behave Differently Than Other HRT Routes

Hormone pellets are placed subcutaneously—typically in the upper gluteal or abdominal area—using a minor in-office procedure with a blunt trocar. Once implanted, they dissolve gradually, releasing hormones into the bloodstream. Research shows this creates an initial peak within days to weeks, followed by near-zero-order release that tapers over 3–6 months, depending on dose and formulation (McCullough, 2014).

In contrast, injections cause supraphysiological spikes followed by troughs, often leading to mood and energy rollercoasters. Transdermal patches or gels provide the smoothest daily profile but require consistent daily application. Oral therapies undergo first-pass hepatic metabolism, which can more dramatically alter binding proteins such as sex hormone-binding globulin (SHBG).

Clinical implication in my observations: Patients transitioning from other routes frequently note fewer daily fluctuations with pellets but may experience early “surge” symptoms. This is why I schedule symptom diaries and targeted lab timing relative to the insertion date—typically an optional check at days 7–14 for peaks, then a core assessment at weeks 4–6, when stabilization begins. Misinterpreting early labs without context can lead to over-adjustment and unnecessary dose changes.

Building a Reliable Post-Pellet Care System

To empower patients and streamline care, I have developed a structured clinic workflow rooted in functional medicine principles. Immediately after insertion, I provide clear instructions on expected timelines, red-flag symptoms (e.g., severe bleeding, infection at the site, chest pain), and a symptom diary template covering energy, mood, sleep, libido, headaches, breast tenderness, bleeding, acne, and hair changes.

Labs are timed strategically: early optional checks for symptomatic peaks, then comprehensive panels at week 4–6, including total/free testosterone, estradiol, progesterone, SHBG, DHT (if hair/skin concerns), CBC (hematocrit/hemoglobin), metabolic panel, liver enzymes, and lipids. Secure messaging and telehealth follow-ups at 2 and 6 weeks keep communication open. Staff training ensures consistent triage, and I personalize transitions if patients wish to switch routes.

Why this system works: It activates patient support early, prevents confusion, and aligns interventions with the patient’s pharmacokinetic curve. In my El Paso practice, this approach has dramatically reduced urgent calls and improved patient confidence and adherence.

Physiologic Architecture of Sex Steroid Hormones: A Clinical Narrative

At the heart of effective post-pellet HRT lies a deep understanding of endocrine physiology. The HPG axis operates through elegant feedback loops: the hypothalamus secretes gonadotropin-releasing hormone (GnRH) in pulses, stimulating the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These drive gonadal production of testosterone (in testes or ovaries/adrenals) and estradiol. Negative feedback from circulating hormones normally keeps levels stable; however, exogenous pellets suppress endogenous production, making external delivery the primary source.

Tissue-level conversions add another layer. Aromatase enzyme in adipose tissue converts testosterone to estradiol—explaining why patients with higher BMI may experience relatively greater estrogen effects from the same testosterone dose. Conversely, 5-alpha-reductase in the skin and scalp converts testosterone to the more potent dihydrotestosterone (DHT), which binds to androgen receptors with higher affinity and can drive acne, oiliness, or hair follicle miniaturization.

SHBG plays a pivotal role as a binding protein produced by the liver. High SHBG (often elevated by oral estrogens or certain thyroid states) sequesters hormones, reducing the free (bioavailable) fraction. Low SHBG—common in insulin resistance—frees more hormone, potentially intensifying androgen or estrogen symptoms. Progesterone counters unopposed estrogen on the endometrium and exerts GABAergic neuromodulatory effects in the brain, promoting calm and better sleep.

Why symptoms fluctuate after pellets: Early post-insertion peaks activate receptors more intensely, while later declines may unmask deficiencies. Integrative chiropractic care supports this physiology by optimizing autonomic balance; adjustments can reduce cortisol-driven insulin resistance, which lowers SHBG, thereby improving free hormone dynamics (as observed in my functional medicine cases).

Evidence-Guided Monitoring: Timing, Metrics, and Clinical Reasoning

I never rely on labs in isolation. Week 1–2 checks capture peaks when symptoms are marked; weeks 4–6 provide the stabilization window for core decisions. Metrics include hormones, safety labs (blood pressure, hematocrit, liver enzymes), metabolic markers (fasting insulin/glucose, lipids), and validated symptom scales.

Interpreting results requires context: a “high” total testosterone with elevated SHBG may still indicate low free hormone. Ferritin levels below 50–70 ng/mL can worsen hair shedding independently of hormones. This evidence-based timing prevents overreaction to transient changes while catching clinically meaningful trends (Jacobsen et al., 2025).

Structured Troubleshooting: Post-Pellet Symptom Patterns and Solutions

Managing Post-Pellet Androgen Excess in Women: Irritability, Acne, and Hair Changes

Early irritability, acne, or scalp oiliness often signals elevated free testosterone or DHT conversion via 5-alpha-reductase. Physiology: DHT binds scalp receptors, shortening the anagen (growth) phase and miniaturizing follicles. In my practice, I confirm timing, order labs (total/free T, DHT, SHBG, ferritin, TSH), and allow 1–2 weeks for settling unless severe. For DHT-driven issues, I discuss finasteride or dutasteride cautiously in women (with clear informed consent), alongside topical minoxidil and ferritin optimization if low. Route changes to transdermal or lower-dose future pellets minimize surges. Why this works: Inhibiting 5-alpha-reductase directly reduces DHT’s impact on follicles (Iamsumang et al., 2020).

Managing Post-Pellet Estradiol Fluctuations: Bleeding, Headaches, and Mood

Breast tenderness, spotting, or headaches reflect early estradiol peaks acting on estrogen-sensitive tissues. In women with a uterus, unopposed estrogen proliferates the endometrium, risking bleeding without progesterone opposition. Progesterone induces the secretory phase, stabilizing the lining and exerting GABAergic calming effects. I add oral micronized progesterone (100–200 mg nightly, cyclic or continuous) based on menopausal status and monitor with ultrasound if bleeding persists. Headaches benefit from hydration, magnesium, and steadier transdermal routes.

Rationale: Guidelines emphasize progesterone for endometrial protection to prevent hyperplasia (Harper-Harrison et al., 2024). Transdermal delivery avoids first-pass effects and vascular reactivity spikes.

Transitioning Off Pellets: Stepwise Protocols for Stable HRT

Pellets cannot be removed easily once dissolved; release continues for months. I map the decay curve, introduce bridging transdermal therapy, or low-dose cream/gel as levels wane, and use symptom diaries and serial labs to guide timing. Progesterone is tapered with declining estradiol. What: Abrupt deficits cause rebound symptoms; controlled bridging maintains receptor stability and safety.

Hair Changes After HRT Pellets: DHT, Ferritin, Thyroid, and Targeted Support

DHT miniaturizes follicles; low ferritin impairs cycling; thyroid imbalance compounds shedding. I target labs and intervene with iron repletion, minoxidil, selective 5-alpha-reductase inhibitors, and route adjustments. Hair regrowth lags 8–12 weeks due to slow follicular physiology.

Post-Pellet Anxiety, Irritability, and Sleep Disturbance: Neuroendocrine Balancing

Sudden neurosteroid shifts affect GABA tone. Nighttime progesterone helps restore balance; chiropractic adjustments further reduce stress axis overactivation. Behavioral strategies and magnesium complement this for rapid stabilization.

Safety First: Guardrails, Contraindications, and Special Populations

I monitor hematocrit (testosterone can elevate it), blood pressure, and bleeding. Transdermal routes are preferred for patients at risk of thrombosis or migraine. Genetic factors (e.g., SRD5A2 variants that increase DHT) and comorbidities such as PCOS (low SHBG, insulin resistance) guide personalization. Chiropractic care helps improve mobility and reduce systemic inflammation in these patients.

Comparing Routes: Pellets vs. Injections vs. Transdermal

Pellets offer procedural convenience but early peaks; injections create pronounced swings; transdermal provides the steadiest profile. I help patients choose based on lifestyle, risk, and symptom patterns.

Practical Algorithms: Step-by-Step Post-Pellet Management

1. Assess timing post-insertion.
2. Categorize symptoms.
3. Order targeted labs.
4. Intervene physiologically (e.g., progesterone for endometrium, DHT modulation for hair).
5. Follow up and refine.

This algorithm, refined through years of observation, transforms variability into predictable management.

Case-Style Illustrations

Consider a 50-year-old perimenopausal woman with week-3 spotting and hair shedding: I add progesterone, check labs/ferritin, start minoxidil, and plan route adjustments—resolving both issues within weeks. Another case of early irritability and headaches responds to hydration, magnesium, and progesterone, with a future transdermal preference.

Advanced Considerations: Lab Nuances, SHBG, and Symptom Interpretation

SHBG is a key biomarker: insulin resistance lowers SHBG levels, thereby increasing free hormones (Ding et al., 2009). Lifestyle interventions raise SHBG and stabilize therapy. Local implant-site inflammation is usually self-limited; persistent issues warrant evaluation.

Quality Improvement and Patient Education

I track outcomes, use standardized checklists, and provide clear “what to expect” guides. Patients learn to call for red flags while normalizing transient peaks.

Research Landscape: Contemporary Evidence and Consensus

While large randomized trials on pellets are limited compared to other routes, observational data and pharmacokinetic studies support their role when closely monitored (American College of Obstetricians and Gynecologists, 2023; Wender et al., 2025). Emphasis remains on personalization, endometrial protection, and hematocrit surveillance.

My Approach as Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

In my integrative practice, I combine evidence-based pellet therapy with chiropractic care to address root causes—nervous system dysregulation, gut-hormone links, and metabolic health. This holistic lens has consistently improved patient vitality and satisfaction.

Summary

Post-pellet HRT demands understanding of pharmacokinetics, physiology, and individualized care. Early peaks are manageable with education and timely interventions. Progesterone protects the endometrium, DHT modulation addresses hair/skin concerns, and route selection minimizes risks. Integrative chiropractic care enhances outcomes by supporting autonomic and structural balance. Lab timing at 4–6 weeks anchors decisions; safety monitoring is non-negotiable. Through structured workflows and shared decision-making, we achieve confident, compassionate hormone optimization.

Conclusion

By embracing physiology-aware protocols, symptom diaries, and precise adjustments, post-pellet challenges become predictable opportunities for fine-tuning. My goal remains empowering patients with modern, evidence-based care that honors their unique biology and life stage.

References

• American College of Obstetricians and Gynecologists. (2023). Compounded bioidentical hormone therapy. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2023/xx/xx
• Ding, E. L., et al. (2009). Sex hormone-binding globulin and risk of type 2 diabetes in women and men. New England Journal of Medicine, 361(12), 1152–1163. https://www.nejm.org/doi/full/10.1056/NEJMoa0804381
• Harper-Harrison, G., et al. (2024). Hormone replacement therapy. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK493191/
• Iamsumang, W., et al. (2020). Finasteride and its potential for treating female pattern hair loss. Drug Design, Development and Therapy, 14, 1297–1305. https://pmc.ncbi.nlm.nih.gov/articles/PMC7060023/
• Jacobsen, L., et al. (2025). Subcutaneous estradiol pellets as hormone therapy in menopausal women. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12786477/
• McCullough, A. (2014). A review of testosterone pellets in the treatment of hypogonadism. Current Sexual Health Reports, 6(3), 165–172. https://pmc.ncbi.nlm.nih.gov/articles/PMC4431706/
• Pastuszak, A. W., et al. (2012). Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. Journal of Andrology, 33(5), 927–937. https://pubmed.ncbi.nlm.nih.gov/22403285/
• Wender, M. C. O., et al. (2025). Compounded hormonal pellets: A critical review. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12341420/

SEO Tags:

post-pellet HRT, hormone pellet therapy side effects, managing androgen excess after pellets, estrogen fluctuations, bleeding headaches HRT, transitioning off hormone pellets, hair loss after testosterone pellets in women, SHBG insulin resistance HRT, integrative chiropractic hormone therapy, bioidentical hormone pellets El Paso, evidence-based post-pellet care